Single-Dose Liposomal Amphotericin B Treatment for Cryptococcal Meningitis

Abstract

BACKGROUND: Cryptococcal meningitis is a leading cause of human immunodeficiency virus (HIV)-related death in sub-Saharan Africa. Whether a treatment regimen that includes a single high dose of liposomal amphotericin B would be efficacious is not known. METHODS: In this phase 3 randomized, controlled, noninferiority trial conducted in five African countries, we assigned HIV-positive adults with cryptococcal meningitis in a 1:1 ratio to receive either a single high dose of liposomal amphotericin B (10 mg per kilogram of body weight) on day 1 plus 14 days of flucytosine (100 mg per kilogram per day) and fluconazole (1200 mg per day) or the current World Health Organization-recommended treatment, which includes amphotericin B deoxycholate (1 mg per kilogram per day) plus flucytosine (100 mg per kilogram per day) for 7 days, followed by fluconazole (1200 mg per day) for 7 days (control). The primary end point was death from any cause at 10 weeks; the trial was powered to show noninferiority at a 10-percentage-point margin. RESULTS: CFU per milliliter per day in the control group. Fewer participants had grade 3 or 4 adverse events in the liposomal amphotericin B group than in the control group (50.0% vs. 62.3%). CONCLUSIONS: Single-dose liposomal amphotericin B combined with flucytosine and fluconazole was noninferior to the WHO-recommended treatment for HIV-associated cryptococcal meningitis and was associated with fewer adverse events. (Funded by the European and Developing Countries Clinical Trials Partnership and others; Ambition ISRCTN number, ISRCTN72509687.).

Shown for reading. Its publisher allows quoting it, not republishing it.

References 33

1. 1.
   Adult meningitis in a setting of high HIV and TB prevalence: findings from 4961 suspected cases · 2010

   No notice
2. 2.

   Tenforde MW, Mokomane M, Leeme T, et al. Epidemiology of adult meningitis during antiretroviral therapy scale-up in southern Africa: Results from the Botswana national meningitis survey. J Infect. 2019;79:212-9.

   Not in our library10.1016/j.jinf.2019.06.013

3. 3.

   Durski KN, Kuntz KM, Yasukawa K, Virnig BA, Meya DB, Boulware DR. Cost-effective diagnostic checklists for meningitis in resource-limited settings. J Acquir Immune Defic Syndr. 2013;63:e101-8.

   Not in our library10.1097/qai.0b013e31828e1e56

4. 4.

   Rajasingham R, Smith RM, Park BJ, et al. Global burden of disease of HIV-associated cryptococcal meningitis: an updated analysis. Lancet Infect Dis. 2017;17:873-81.

   Not in our library10.1016/s1473-3099(17)30243-8

5. 5.
   Persistent High Burden of Advanced HIV Disease Among Patients Seeking Care in South Africa’s National HIV Program: Data From a Nationwide Laboratory Cohort · 2018

   No notice
6. 6.

   Leeme TB, Mine M, Lechiile K, et al. Utility of CD4 count measurement in the era of universal antiretroviral therapy: an analysis of routine laboratory data in Botswana. HIV Med. 2021;22:1-10.

   Not in our library10.1111/hiv.12951

7. 7.
   The Continuing Burden of Advanced HIV Disease Over 10 Years of Increasing Antiretroviral Therapy Coverage in South Africa · 2018

   No notice
8. 8.

   Tenforde MW, Mokomane M, Leeme T, et al. Advanced human immunodeficiency virus disease in botswana following successful antiretroviral therapy rollout: Incidence of and temporal trends in cryptococcal meningitis. Clin Infect Dis. 2017;65:779-86.

   Not in our library10.1093/cid/cix430

9. 9.

   Bicanic T, Bottomley C, Loyse A, et al. Toxicity of Amphotericin B Deoxycholate-Based Induction Therapy in Patients with HIV-Associated Cryptococcal Meningitis. Antimicrob Agents Chemother. 2015;59:7224-31.

   Not in our library10.1128/aac.01698-15

10. 10.

    Tenforde MW, Gertz AM, Lawrence DS, et al. Mortality from HIV-associated meningitis in sub-Saharan Africa: a systematic review and meta-analysis. J Int AIDS Soc. 2020;23:e25416.

    Not in our library10.1002/jia2.25416

11. 11.

    Guidelines for the diagnosis, prevention, and management of cryptococcal disease in HIV-infected adults, adolescents and children. 2018.

    Not in our library

12. 12.

    Molloy SF, Kanyama C, Heyderman RS, et al. Antifungal combinations for treatment of cryptococcal meningitis in Africa. N Engl J Med. 2018;378:1004-17.

    Not in our library10.1056/nejmoa1710922

13. 13.

    Adler-Moore J, Lewis RE, Bruggemann RJM, Rijnders BJA, Groll AH, Walsh TJ. Preclinical Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antifungal Activity of Liposomal Amphotericin B. Clin Infect Dis. 2019;68:S244-S59.

    Not in our library10.1093/cid/ciz064

14. 14.

    Groll AH, Rijnders BJA, Walsh TJ, Adler-Moore J, Lewis RE, Bruggemann RJM. Clinical Pharmacokinetics, Pharmacodynamics, Safety and Efficacy of Liposomal Amphotericin B. Clin Infect Dis. 2019;68:S260-S74.

    Not in our library10.1093/cid/ciz076

15. 15.

    Hamill RJ, Sobel JD, El-Sadr W, et al. Comparison of 2 doses of liposomal amphotericin B and conventional amphotericin B deoxycholate for treatment of AIDS-associated acute cryptococcal meningitis: a randomized, double-blind clinical trial of efficacy and safety. Clin Infect Dis. 2010;51:225-32.

    Not in our library10.1086/653606

16. 16.

    Hope WW, Goodwin J, Felton TW, Ellis M, Stevens DA. Population pharmacokinetics of conventional and intermittent dosing of liposomal amphotericin B in adults: a first critical step for rational design of innovative regimens. Antimicrob Agents Chemother. 2012;56:5303-8.

    Not in our library10.1128/aac.00933-12

17. 17.

    O’Connor L, Livermore J, Sharp AD, et al. Pharmacodynamics of liposomal amphotericin B and flucytosine for cryptococcal meningoencephalitis: safe and effective regimens for immunocompromised patients. J Infect Dis. 2013;208:351-61.

    Not in our library10.1093/infdis/jit164

18. 18.

    Gubbins PO, Amsden JR, McConnell SA, Anaissie EJ. Pharmacokinetics and buccal mucosal concentrations of a 15 milligram per kilogram of body weight total dose of liposomal amphotericin B administered as a single dose (15 mg/kg), weekly dose (7.5 mg/kg), or daily dose (1 mg/kg) in peripheral stem cell transplant patients. Antimicrob Agents Chemother. 2009;53:3664-74.

    Not in our library10.1128/aac.01448-08

19. 19.

    Vogelsinger H, Weiler S, Djanani A, et al. Amphotericin B tissue distribution in autopsy material after treatment with liposomal amphotericin B and amphotericin B colloidal dispersion. J Antimicrob Chemother. 2006;57:1153-60.

    Not in our library10.1093/jac/dkl141

20. 20.

    Groll AH, Giri N, Petraitis V, et al. Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental Candida albicans infection of the central nervous system. J Infect Dis. 2000;182:274-82.

    Not in our library10.1086/315643

21. 21.

    Sundar S, Chakravarty J, Agarwal D, Rai M, Murray HW. Single-dose liposomal amphotericin B for visceral leishmaniasis in India. N Engl J Med. 2010;362:504-12.

    Not in our library10.1056/nejmoa0903627

22. 22.

    Albert MM, Stahl-Carroll L, Luther MF, Graybill JR. Comparison of liposomal amphotericin B to amphotericin B for treatment of murine cryptococcal meningitis. J Med Mycol. 1995;5:1-6.

    Not in our library

23. 23.

    Lestner J, McEntee L, Johnson A, et al. Experimental Models of Short Courses of Liposomal Amphotericin B for Induction Therapy for Cryptococcal Meningitis. Antimicrob Agents Chemother. 2017;61:e00090-17.

    Not in our library10.1128/aac.00090-17

24. 24.

    Jarvis JN, Leeme TB, Molefi M, et al. Short-course High-dose Liposomal Amphotericin B for Human Immunodeficiency Virus-associated Cryptococcal Meningitis: A Phase 2 Randomized Controlled Trial. Clin Infect Dis. 2019;68:393-401.

    Not in our library10.1093/cid/ciy515

25. 25.

    Lee JW, Amantea MA, Francis PA, et al. Pharmacokinetics and safety of a unilamellar liposomal formulation of amphotericin B (AmBisome) in rabbits. Antimicrob Agents Chemother. 1994;38:713-8.

    Not in our library10.1128/aac.38.4.713

26. 26.

    Lawrence DS, Youssouf N, Molloy SF, et al. AMBIsome Therapy Induction OptimisatioN (AMBITION): High Dose AmBisome for Cryptococcal Meningitis Induction Therapy in sub-Saharan Africa: Study Protocol for a Phase 3 Randomised Controlled Non-Inferiority Trial. Trials. 2018;19:649.

    Not in our library10.1186/s13063-018-3026-4

27. 27.

    Jackson AT, Nussbaum JC, Phulusa J, et al. A phase II randomized controlled trial adding oral flucytosine to high-dose fluconazole, with short-course amphotericin B, for cryptococcal meningitis. AIDS. 2012;26:1363-70.

    Not in our library10.1097/qad.0b013e328354b419

28. 28.

    Brouwer AE, Rajanuwong A, Chierakul W, et al. Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial. Lancet. 2004;363:1764-7.

    Not in our library10.1016/s0140-6736(04)16301-0

29. 29.

    Beardsley J, Wolbers M, Kibengo FM, et al. Adjunctive dexamethasone in HIV-associated cryptococcal meningitis. N Engl J Med. 2016;374:542-54.

    Not in our library10.1056/nejmoa1509024

30. 30.

    Day JN, Chau TT, Wolbers M, et al. Combination antifungal therapy for cryptococcal meningitis. N Engl J Med. 2013;368:1291-302.

    Not in our library10.1056/nejmoa1110404

31. 31.

    Boulware DR, Meya DB, Muzoora C, et al. Timing of antiretroviral therapy after diagnosis of cryptococcal meningitis. N Engl J Med. 2014;370:2487-98.

    Not in our library10.1056/nejmoa1312884

32. 32.

    Johnson PC, Wheat LJ, Cloud GA, et al. Safety and efficacy of liposomal amphotericin B compared with conventional amphotericin B for induction therapy of histoplasmosis in patients with AIDS. Ann Intern Med. 2002;137:105-9.

    Not in our library10.7326/0003-4819-137-2-200207160-00008

33. 33.

    Garcia A, Adler-Moore JP, Proffitt RT. Single-dose AmBisome (Liposomal amphotericin B) as prophylaxis for murine systemic candidiasis and histoplasmosis. Antimicrob Agents Chemother. 2000;44:2327-32.

    Not in our library10.1128/aac.44.9.2327-2332.2000

Cited by papers we hold 2

• Cryptococcus neoformans, a global threat to human health · 2023
  No notice
• The importance of antimicrobial resistance in medical mycology · 2022
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.